April 2, 2025
On March 24, REGENXBIO Inc. shared a Letter to the Duchenne Community announcing updates to their RGX-202 AFFINITY DUCHENNE gene therapy for the treatment of Duchenne muscular dystrophy.
To view their letter to the Duchenne community, please click here.
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
